Re: Report of exempt distribution on SEDAR
in response to
by
posted on
Sep 10, 2022 10:52AM
RVX has underperformed its Biotechnology & Drugs peers over the last three months and over the past year too.
09/09/2022
Morningstar Rating |
3 stars out of 5 stars |
---|---|
Quantitative Valuation | Under Valued |
Fair ValueQ | 0.44 CAD |
Last price as of Sep 09, 2022 |
-- CAD |
Quantitative Uncertainty | Extreme |
Economic Moat | -- |
Market Cap | 63.1 M |
Country of Domicile | Canada |
Rate of Return Estimate: -- More information about Rate of Return Estimate.